|
|
|
|
|
Black Women and HIV/AIDS: Findings from the Southeast Regional Consumer and Provider Focus Group Interviews
|
Black Women’s Issue Brief No. 2 provides qualitative data from Southeast regional focus groups that occurred from April to August 2009. Particular attention is given to the voice of women living with and affected by HIV/AIDS to provide a clear and fresh perspective on issues and suggestions for health departments to consider when designing, targeting and implementing culturally relevant programs or interventions for black women.
|
|
|
|
|
|
|
|
|
|
|
2009 NASTAD State Budget Cuts Report
|
The 2009 NASTAD State Budget Cuts Report is the summary results of NASTAD’s August 2009 budget cuts survey to HIV and viral hepatitis programs. NASTAD intends to use the data contained in the summary in on-going advocacy for additional federal appropriations as well as contextualizing state fiscal crises regarding HIV and viral hepatitis services.
|
|
|
|
|
Webinar: CDC Division of Viral Hepatitis Prevention Branch Update
|
In partnership with the National Viral Hepatitis Roundtable (NVHR), NASTAD hosted a webinar featuring Geoff Beckett, PA-C, MPH, Chief of the Prevention Branch, CDC Division of Viral Hepatitis. The webinar included updates on the Program Operations, Training and Education and Research and Evaluation Teams of CDC Division of Viral Hepatitis.
|
|
|
National HIV Prevention Inventory
|
NASTAD and the Kaiser Family Foundation partnered to produce this report that offers a baseline picture of how HIV prevention is delivered across the country. The report is based on a survey of 65 health departments, including all state and territorial jurisdictions and six CDC directly funded U.S. cities and provides a comprehensive inventory of HIV prevention efforts at state and local levels.
|
|
|
H1N1 Influenza Virus Information
|
| The Centers for Disease Control and Prevention has issued interim guidance on H1N1 influenza virus in HIV infected individuals. To summarize, patients with HIV are at higher risk for more severe influenza and should be treated as high risk individuals. There are no absolute contraindications for co-administration of oseltamivir or zanamivir, the two drugs recommended to be used for prevention and treatment of H1N1, with currently available antiretroviral medications. | |
|
|
|
|